Company intelligence / Profile preview

LE2025 Therapeutics AG

Basel, Basel-Stadt, Switzerland

Ownership: Private
Development stage: Other

Overview

WIN027 (QX027N), a long-acting bispecific antibody targeting TSLP and IL-13, completed Phase 1 with confirmed extended half-life, low antidrug antibodies, and good tolerability up to highest dose

Therapeutic areas: PulmonologyDermatology
Modalities: Bispecific monoclonal antibody
Industry: Biotech

Partnerships

Qyuns Therapeutics

Beyond the preview

Go deeper on LE2025 Therapeutics AG.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LE2025 Therapeutics AG.

Explore the full profile